Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) Cost of Revenue: 2013-2025

Historic Cost of Revenue for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $11.2 million.

  • CorMedix's Cost of Revenue rose 65.75% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.3 million, marking a year-over-year increase of 23.55%. This contributed to the annual value of $28.7 million for FY2024, which is 58.63% up from last year.
  • As of Q3 2025, CorMedix's Cost of Revenue stood at $11.2 million, which was up 75.22% from $6.4 million recorded in Q2 2025.
  • CorMedix's 5-year Cost of Revenue high stood at $11.2 million for Q3 2025, and its period low was $332 during Q2 2022.
  • Over the past 3 years, CorMedix's median Cost of Revenue value was $6.4 million (recorded in 2025), while the average stood at $6.5 million.
  • As far as peak fluctuations go, CorMedix's Cost of Revenue plummeted by 99.15% in 2022, and later soared by 980,637.05% in 2023.
  • CorMedix's Cost of Revenue (Quarterly) stood at $48,007 in 2021, then plummeted by 99.15% to $406 in 2022, then spiked by 276,171.48% to $4.1 million in 2023, then surged by 66.29% to $8.3 million in 2024, then surged by 65.75% to $11.2 million in 2025.
  • Its Cost of Revenue was $11.2 million in Q3 2025, compared to $6.4 million in Q2 2025 and $4.5 million in Q1 2025.